Amneal Pharmaceuticals, Inc. AMRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Affordable Medicines | $423.24M-3.1% | $436.65M-5.2% | $460.74M+6.3% | $433.43M+4.5% | $414.71M-5.6% | |
| AvKARE | $166.02M-21.2% | $210.74M+6.1% | $198.53M+21.8% | $163.04M-5.4% | $172.42M+1.2% | |
| Specialty | $133.27M— | —— | $125.24M-2.2% | $128.04M+18.2% | $108.3M— | |
| Net revenue by Product | ||||||
| Auto-Injector | $41.91M+7.2% | $39.1M-50.5% | $78.94M+18.5% | $66.59M+38.3% | $48.16M+27.0% | |
| Biosimilar | $22.3M-24.2% | $29.43M+73.0% | $17.01M-32.6% | $25.25M-11.5% | $28.54M-26.0% | |
| Central nervous system | $83.38M-20.4% | $104.75M+34.9% | $77.63M-6.9% | $83.43M+23.4% | $67.61M-11.7% | |
| Distribution | $89.15M-17.2% | $107.68M+11.9% | $96.22M-3.5% | $99.66M-5.0% | $104.9M-1.5% | |
| Government label | $59.95M-30.9% | $86.79M-1.1% | $87.76M+93.2% | $45.42M-9.4% | $50.14M+7.0% | |
| Hormonal / allergy | $35.93M-24.6% | $47.63M+26.4% | $37.69M+6.4% | $35.42M+3.6% | $34.2M-7.6% | |
| Injectable | $49.94M+33.4% | $37.44M-31.1% | $54.37M+56.9% | $34.65M-0.4% | $34.79M-27.5% | |
| Institutional | $9.82M+17.1% | $8.38M+43.2% | $5.85M-42.2% | $10.13M-8.0% | $11.01M+2.6% | |
| International | $5.32M+96.9% | $2.7M-57.0% | $6.29M+231% | $1.9M+54.1% | $1.23M-4.6% | |
| Oral liquid | $12.09M-19.3% | $14.98M-8.7% | $16.42M-8.2% | $17.88M-24.1% | $23.55M-5.3% | |
| Oral solid | $171.1M-9.3% | $188.71M+4.6% | $180.46M+1.2% | $178.26M-0.4% | $178.95M-2.2% | |
| Other dosage forms | $46.61M-31.6% | $68.15M+14.2% | $59.66M-12.5% | $68.19M+20.8% | $56.42M-4.3% | |
| Other therapeutic classes | $13.95M-4.1% | $14.55M+46.6% | $9.92M+14.1% | $8.7M+34.1% | $6.49M-10.5% | |
| Subtotal dosage forms | $417.92M-3.7% | $433.95M-4.5% | $454.45M+5.3% | $431.52M+4.4% | $413.47M-5.6% | |
| Subtotal therapeutic classes | $133.27M-20.2% | $166.93M+33.3% | $125.24M-1.8% | $127.54M+17.8% | $108.3M-10.4% | |
| Transdermal | $73.96M+31.7% | $56.14M+17.9% | $47.6M+16.9% | $40.71M-5.5% | $43.06M-8.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
